Stilla Technologies, a Paris company developing a PCR device that detects and quantifies DNA mutations, completed a $22 million Series B round with a new China investor, TUS-Holdings, participating. TUS-Holdings is associated with Tsinghua University and the Tsinghua Science Park in Nanjing. An incubator, it has $30 billion in capital under management. The head of TUS' European subsidiary, Daniel Wang, will join the Stilla board. Stilla said that the relationship will extend its presence in China, which is already established through a partnership with Apexbio/Cycloud. More details....
Share this with colleagues: